Phase 3 N=12 Hydrocortisone for Term Hypotension
Infant, Newborn, Diseases · Cardiovascular Insufficiency
Primary: Death — 6; 6; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=800 Hydrocortisone for BPD
Infant, Newborn · Infant, Small for Gestational Age · Infant, Very Low Birth Weight
Primary: Survival Without Moderate/Severe Physiologic Bronchopulmonary Dysplasia (BPD) — 332; 349; 66; 53 Participants
Phase 1 N=14 An Investigational Study of Hydrocortisone
Adrenal Insufficiency
Primary: Maximum Serum Concentration (Cmax) — 940.012; 896.489; 1563.479 nmol/L
Phase 4 N=60 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)
Adrenal Insufficiency
Primary: Change in Cognition After 10 Weeks of Treatment With a Low Dose of Hydrocortisone Compared to 10 Weeks of Treatment With a High Dose of Hydrocortisone. — -0.41; -0.42…
Phase 3 N=64 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
Adrenal Insufficiency
Primary: Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma After Multiple Doses During Part A — 3962.0; 4879.6 hour*nanomole…
Phase 1 N=11 Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · Hyperplasia · Adrenal Hyperplasia
Primary: Cortisol Exposure — 110 hr*mcg/dL
Phase 2 N=103 Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids
Internal Hemorrhoids
Primary: Reduction in Swelling — 2.3; 2.0 scores on a scale — p=0.8918
Phase 2 N=64 Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants
Bronchopulmonary Dysplasia · Encephalomalacia · Premature Birth
Primary: Total Cerebral Volume as Measured by Volumetric Brain MRI — 272.01; 277.82 cm^3
N/A N=120 Initiation of Hydrocortisone for the Treatment of Septic Shock
Septic Shock
Primary: 28-day Mortality — 19; 23 Participants
Phase 2 N=14 Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
Phase 2 N=84 HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients
Septic Shock
Primary: Time to Resolution of Shock — 89; 84 Hours
Phase 3 N=55 Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Percentage of Participants Who Were Biochemical Responders at Week 28 — 40.0; 14.3 percentage of participants — p=0.0003
Phase 2 N=5 Dexamethasone Treatment of Congenital Adrenal Hyperplasia
Adrenal Hyperplasia, Congenital
Primary: Percent Difference in the Mean Log Transformed Area Under the Curve of 17-hydroxyprogesterone Between Regimens — 3.16; 3.91 Log Mean Area Under the Curve — p=0.09
Phase 1 N=16 Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone
Healthy Subjects
Primary: Maximum Plasma Concentration (Cmax) of Infacort vs Hydrocortisone — 601.843; 622.384 nmol/L
Phase 2 N=16 Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH
Endocrine Disease · Adrenal Insufficiency · Congenital Adrenal Hyperplasia
Primary: Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia — 601.213 nmol/L
Phase 1 N=18 Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only
Healthy
Primary: Chronocort Cmax — 549.49; 708.46; 856.36 nmol/L
Phase 3 N=122 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Change From Baseline to 24 Weeks of the Mean of the 24-hour Standard Deviation Score (SDS) Profile for 17-OHP — -0.403; -0.172 Z-score — p==0.5521
Phase 2 N=24 Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study
Psoriasis
Primary: Proportion of Patients in the Study With Hypothalamic Pituitary Adrenal (HPA) Axis Suppression — 2; 3 participants
Phase 2 N=33 Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds
Psoriasis Vulgaris
Primary: The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 and 60 Minutes — 29; 1 Participants
Phase 2 N=18 Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease
Cardiac Output, Low
Primary: Blood Pressure. — 6; 5.89 mmHg
Phase 2 N=50 DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: The Percentage of Subjects With HPA Axis Suppression. — 36.4; 12.5 percentage of participants — p=0.086
Phase 2 N=50 Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest
Cardiac Arrest
Primary: Time to Shock Reversal — 55; 49 hours
Phase 4 N=72 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia
Hyperglycemia
Primary: Mean Blood Glucose of All Readings — 157.2; 181.8 mg/dL
Phase 4 N=25 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Adherence to Locoid — .55; .60; .50 percentage of days
Phase 3 N=310 Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
Perennial Allergic Rhinitis
Primary: Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-24h) at Baseline — 183.2; 171.7; 173.1; 172.8 mcg•h/dL
Phase 4 N=19 Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
Psoriasis · Atopic Dermatitis
Primary: Post-injection Serum Cortisol Level — 1 participants
Phase 4 N=56 Cutivate Lotion HPA Axis Pediatric Study
Atopic Dermatitis
Primary: Post Treatment Serum Cortisol Values Will be Compared. — 1 participants
Phase 4 N=50 Comparative Study Between Hydrocortisone and Mannitol in Treatment of Postdural Puncture Headache
Headache
Primary: Number of Patients (in Digits) Got Earlier Relief of PDPH (in Hours) After Use of Hydrocortisone or Mannitol. — 25; 25 Participants
Phase 4 N=30 Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy
Asthma · Rheumatic Disease
Primary: Rey Auditory Verbal Learning Test (RAVLT) — 44.8; 44.1 words
Phase 4 N=37 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Hyperglycemia · Diabetes Mellitus
Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35